Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Gut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, a growing body of evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert a substantial influence on the function and composition of the...
Saved in:
Main Authors: | Yi Zhang, Chengjun Mo, Penghui Ai, Xiaoqin He, Qin Xiao, Xiaodong Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Gut Microbes |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2454937 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving breast cancer treatments using pharmacomicrobiomics
by: Aswin Anand Pai, et al.
Published: (2025-02-01) -
The Role of the Gastrointestinal Microbiota in Parkinson’s Disease
by: Maurizio Gabrielli, et al.
Published: (2024-12-01) -
The Microbiome-Gut-Brain Axis, Nutrition and Parkinson’s Disease
by: Jevgenija Guk, et al.
Published: (2024-03-01) -
Gut–brain axis and environmental factors in Parkinson’s disease: bidirectional link between disease onset and progression
by: Soo Jung Park, et al.
Published: (2025-12-01) -
Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024
by: Jieling Liang, et al.
Published: (2025-01-01)